Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
BMY•Bristol Myers Squibb and partner SystImmune said their experimental breast cancer drug reduced the risk of disease worsening or death by 59% in a late-stage study. Patients lived an average of 8.2 months without their cancer growing, versus four months with standard chemotherapy.
1. Study results
Izalontamab brengitecan reduced the risk of disease worsening or death by 59% in patients with advanced hormone-receptor-positive, HER2-negative breast cancer who had failed at least one prior line of chemotherapy. Patients treated with the drug lived an average of 8.2 months without their cancer growing, compared with four months for those receiving standard chemotherapy.
2. Results presentation
Full results will be presented at the European Society for Medical Oncology congress in Madrid.
